Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451464
Status:
COMPLETED
Last Update Posted:
2007-03-23
First Post:
2007-03-22
Brief Title:
Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients
Status:
COMPLETED
Status Verified Date:
2005-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cardiovascular-related diseases have been the majorities of the leading ten causes of death in Taiwan Atherosclerotic cardiovascular diseases are multifactorial Some non-modifiable risk factors eg genetic trait may attenuate the benefit of risk modification of the modifiable factors eg the effect of drug treatment Genetic epidemiology has being widely used to analyze the underline risk of cardiovascular diseases and to point the direction of treatment or prevention
Lipoprotein is composed of lipid and protein The genetic variation or mutation of apolipoprotein the protein of lipoprotein has been linked to some lipid abnormality resulting severe atherosclerotic cardiovascular diseases ApoA-I apo A-II apo A-IV apo B100 apo B48 apo C-I apo C-II apo C-III apo D and apo E are currently thought to affect lipid abnormalities In addition it has been documented that genetic variations are presented among different races Apolipoprotein genetic variations or genetic polymorphism study has been emerged as an important role in the field of genetic therapy The purpose of this 3-year study is to continue the lipid study in our laboratory identifying the apolipoprotein genotyping in our pooled hyperlipidemic patients and normal control subjects living in Taiwan We will observe the incidence and link apo A-I apo A-II apo A-IV and apo C-III genetic variations to the related lipid abnormality and cardiovascular diseases The changes of genotyping after lipid lowering drug treatment using statin or fibrate in hypercholesterolemic or hypertriglyceridemic patients is another goal of this project
Lipoprotein is composed of lipid and protein The genetic variation or mutation of apolipoprotein the protein of lipoprotein has been linked to some lipid abnormality resulting severe atherosclerotic cardiovascular diseases ApoA-I apo A-II apo A-IV apo B100 apo B48 apo C-I apo C-II apo C-III apo D and apo E are currently thought to affect lipid abnormalities In addition it has been documented that genetic variations are presented among different races Apolipoprotein genetic variations or genetic polymorphism study has been emerged as an important role in the field of genetic therapy The purpose of this 3-year study is to continue the lipid study in our laboratory identifying the apolipoprotein genotyping in our pooled hyperlipidemic patients and normal control subjects living in Taiwan We will observe the incidence and link apo A-I apo A-II apo A-IV and apo C-III genetic variations to the related lipid abnormality and cardiovascular diseases The changes of genotyping after lipid lowering drug treatment using statin or fibrate in hypercholesterolemic or hypertriglyceridemic patients is another goal of this project
Detailed Description:
Cardiovascular-related diseases have been the majorities of the leading ten causes of death in Taiwan Atherosclerotic cardiovascular diseases are multifactorial Some non-modifiable risk factors eg genetic trait may attenuate the benefit of risk modification of the modifiable factors eg the effect of drug treatment Genetic epidemiology has being widely used to analyze the underline risk of cardiovascular diseases and to point the direction of treatment or prevention
Lipoprotein is composed of lipid and protein The genetic variation or mutation of apolipoprotein the protein of lipoprotein has been linked to some lipid abnormality resulting severe atherosclerotic cardiovascular diseases ApoA-I apo A-II apo A-IV apo B100 apo B48 apo C-I apo C-II apo C-III apo D and apo E are currently thought to affect lipid abnormalities In addition it has been documented that genetic variations are presented among different races Apolipoprotein genetic variations or genetic polymorphism study has been emerged as an important role in the field of genetic therapy The purpose of this 3-year study is to continue the lipid study in our laboratory identifying the apolipoprotein genotyping in our pooled hyperlipidemic patients and normal control subjects living in Taiwan We will observe the incidence and link apo A-I apo A-II apo A-IV and apo C-III genetic variations to the related lipid abnormality and cardiovascular diseases The changes of genotyping after lipid lowering drug treatment using statin or fibrate in hypercholesterolemic or hypertriglyceridemic patients is another goal of this project
Our results showed ApoC-III 3175NT CG mutation was significantly related to hypertriglyceridemia the same relation was also found in the Apo B exon 29 13132 NT CG 4311 AA Asn Ser mutation It is interesting to find some hot spot mutation among Caucasian population such as Apo B exon 26 10699 NT CA 3500 AA Arg Gln Apo A-IV 1527-2345 NT and Apo E exon 2 mutations were not found in tested samples Most of presented allele frequencies in apolipoteins genes were different between our population and Caucasian population The present results strongly suggest that it is necessary to establish our own genetic data which are linked to diseases
Lipoprotein is composed of lipid and protein The genetic variation or mutation of apolipoprotein the protein of lipoprotein has been linked to some lipid abnormality resulting severe atherosclerotic cardiovascular diseases ApoA-I apo A-II apo A-IV apo B100 apo B48 apo C-I apo C-II apo C-III apo D and apo E are currently thought to affect lipid abnormalities In addition it has been documented that genetic variations are presented among different races Apolipoprotein genetic variations or genetic polymorphism study has been emerged as an important role in the field of genetic therapy The purpose of this 3-year study is to continue the lipid study in our laboratory identifying the apolipoprotein genotyping in our pooled hyperlipidemic patients and normal control subjects living in Taiwan We will observe the incidence and link apo A-I apo A-II apo A-IV and apo C-III genetic variations to the related lipid abnormality and cardiovascular diseases The changes of genotyping after lipid lowering drug treatment using statin or fibrate in hypercholesterolemic or hypertriglyceridemic patients is another goal of this project
Our results showed ApoC-III 3175NT CG mutation was significantly related to hypertriglyceridemia the same relation was also found in the Apo B exon 29 13132 NT CG 4311 AA Asn Ser mutation It is interesting to find some hot spot mutation among Caucasian population such as Apo B exon 26 10699 NT CA 3500 AA Arg Gln Apo A-IV 1527-2345 NT and Apo E exon 2 mutations were not found in tested samples Most of presented allele frequencies in apolipoteins genes were different between our population and Caucasian population The present results strongly suggest that it is necessary to establish our own genetic data which are linked to diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NSC93-2314-B-002-016 | None | None | None |